NewGenIvf Group Limited closed a public offering on September 30, 2026, raising approximately $1.25 million in gross proceeds. The company issued an aggregate of 17,857,143 Class A ordinary shares and pre-funded warrants at a price of $0.07 per share. Aegis Capital Corp. acted as the exclusive placement agent for the best-efforts offering. Net proceeds will fund investments in K25.ai, debt restructuring, working capital for Nodexus machine deployment, and general corporate purposes. Concurrently, officers, directors, and employees entered into 60-day lock-up agreements restricting the sale of their shares. NewGenIvf Group Limited operates in the technology sector with diversified interests in real estate development, digital asset management, and reproductive health solutions.
